Brokerages expect that Spark Therapeutics Inc (NASDAQ:ONCE) will report $53.75 million in sales for the current quarter, Zacks Investment Research reports. Eight analysts have provided estimates for Spark Therapeutics’ earnings, with the lowest sales estimate coming in at $3.00 million and the highest estimate coming in at $119.00 million. Spark Therapeutics reported sales of $1.27 million during the same quarter last year, which would indicate a positive year over year growth rate of 4,132.3%. The business is expected to announce its next earnings report on Tuesday, May 8th.
According to Zacks, analysts expect that Spark Therapeutics will report full-year sales of $53.75 million for the current year, with estimates ranging from $80.00 million to $239.52 million. For the next financial year, analysts anticipate that the firm will report sales of $152.05 million per share, with estimates ranging from $76.99 million to $229.40 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that cover Spark Therapeutics.
Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings data on Tuesday, February 20th. The biotechnology company reported ($1.73) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($1.73). The firm had revenue of $7.41 million during the quarter, compared to analyst estimates of $9.53 million. Spark Therapeutics had a negative net margin of 2,100.80% and a negative return on equity of 59.38%.
A number of equities research analysts have recently weighed in on ONCE shares. SunTrust Banks boosted their price objective on shares of Spark Therapeutics to $113.00 and gave the stock a “buy” rating in a report on Thursday, January 4th. ValuEngine lowered shares of Spark Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. Credit Suisse Group initiated coverage on shares of Spark Therapeutics in a report on Wednesday, January 17th. They issued an “outperform” rating and a $61.00 price objective for the company. Cantor Fitzgerald set a $105.00 price target on shares of Spark Therapeutics and gave the company a “buy” rating in a report on Tuesday, December 19th. Finally, Barclays reiterated a “buy” rating and set a $64.00 price target (up from $61.00) on shares of Spark Therapeutics in a report on Tuesday, January 23rd. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and sixteen have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $70.58.
Several large investors have recently added to or reduced their stakes in the company. BlackRock Inc. grew its position in shares of Spark Therapeutics by 1.4% in the 4th quarter. BlackRock Inc. now owns 2,650,258 shares of the biotechnology company’s stock worth $136,277,000 after buying an additional 35,801 shares during the period. JPMorgan Chase & Co. grew its position in Spark Therapeutics by 15.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,848,988 shares of the biotechnology company’s stock valued at $164,986,000 after purchasing an additional 241,016 shares during the last quarter. Janus Henderson Group PLC grew its position in Spark Therapeutics by 46.4% during the 3rd quarter. Janus Henderson Group PLC now owns 756,088 shares of the biotechnology company’s stock valued at $67,413,000 after purchasing an additional 239,723 shares during the last quarter. Clearbridge Investments LLC grew its position in Spark Therapeutics by 2.9% during the 4th quarter. Clearbridge Investments LLC now owns 687,444 shares of the biotechnology company’s stock valued at $35,348,000 after purchasing an additional 19,492 shares during the last quarter. Finally, Rock Springs Capital Management LP grew its position in Spark Therapeutics by 3.0% during the 4th quarter. Rock Springs Capital Management LP now owns 615,000 shares of the biotechnology company’s stock valued at $31,623,000 after purchasing an additional 18,000 shares during the last quarter. 99.87% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Spark Therapeutics (NASDAQ:ONCE) opened at $61.58 on Friday. The firm has a market cap of $2,334.28, a P/E ratio of -7.97 and a beta of 2.82. Spark Therapeutics has a 1-year low of $41.06 and a 1-year high of $91.75.
About Spark Therapeutics
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.